Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell webs linked to worse outcomes in chest infection

NCT ID NCT07194915

Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examines whether tiny webs released by immune cells, called neutrophil extracellular traps (NETs), are linked to how severe a pleural infection is and the risk of dying within a year. Researchers analyzed fluid from the chest cavity of 326 patients across multiple countries. The goal is to better understand the disease and potentially identify high-risk patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify which patients with pleural infection are at highest risk, guiding more personalized treatment decisions.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patient groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

326 people

The number who actually took part.

Started

Jan 2024

Expected to finish

Oct 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with confirmed pleural infection

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients were included if they had a clinical presentation consistent with pleural infection as stated in the Methods section of the main manuscript and any of the following criteria: 1. Pleural fluid that was macroscopically purulent, OR 2. Pleural fluid that was positive on culture for bacterial infection, OR 3. Pleural fluid that demonstrated bacteria on Gram staining, OR 4. Pleural fluid with pH ≤7.2 (measured in a blood gas analyser) or low glucose level (≤3mmol/L or ≤55mg/dL) in a patient with clinical evidence of infection, OR 5. Contrast-enhanced CT evidence of pleural infection (consolidation of underlying lung with enhancing pleural collection) in a patient with clinical evidence of infection, alongside exclusion of other sources of infection. Exclusion criteria: 1. Age less than 18 years, OR 2. No pleural fluid available for analysis, OR 3. Patient previous pneumonectomy on the side of pleural infection, OR 4. Expected survival less than three months due to co-morbid disease, as judged by the recruiting physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pleural infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation pleural empyema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pleural infection

Contacts and locations

Locations

  • CAMS Oxford Institute, Nuffield Department of Medicine

    Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.